About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Contact Us
Technology
Introduction
Anti-CD3 oral immunotherapy
VaxiSome
Group-common Pneumococcal Vaccine
Alzheimer's Disease
Publications
Pipeline
Overview
Inflammatory and auto-immune diseases
Influenza
Hepatitis B
Pneumococcal
Alzheimer’s Disease
Pandemic Influenza
Anthrax
Partnering
Partnering
Investors
Releases
Events
Stock Info
Financial Reports (Hebrew)
Press Clippings
Releases
Events
Stock Info
Financial Reports (Hebrew)
Press Clippings
Investors
Releases
Releases
Nasvax signes an agreement with Centocor Ortho for oral anti-CD3 immunotherapy
August 24, 2010
PDF (English)
PDF (Hebrew)
Read More
Nasvax receives full approval to start Phase 2a clinical study for oral anti-CD3 immunotherapy in subjects with NASH ("fatty liver")
August 22, 2010
PDF (English)
PDF (Hebrew)
Read More
Nasvax receives approval from the US Patent & Trademark Office for the Vaxisome Technology
August 10, 2010
PDF (English)
PDF (Hebrew)
Read More
Nasvax Clinical Trial Phase II Results
March 28, 2010
PDF (English)
PDF (Hebrew)
Read More
Nasvax Licenses with Hadasit Medical Research
March 28, 2010
PDF (English)
PDF (Hebrew)
Read More
Nasvax Negotiates for License on a new Immunotherapeutic Technology
March 16, 2010
PDF (English)
PDF (Hebrew)
Read More
NasVax Signs a Joint Research and Option for License Agreement with Novartis
February 21, 2010
PDF (English)
PDF (Hebrew)
Read More
NasVax reports positive results for swine flu vaccine
December 20, 2009
PDF (English)
PDF (Hebrew)
Read More
NasVax reports successful initial trial of swine flu vaccine
October 12, 2009
PDF (English)
PDF (Hebrew)
Read More
Protea Vaccine Technologies receives approval in-principal for research grant
September 03, 2009
PDF (English)
PDF (Hebrew)
Read More
NasVax: Closing Share Purchase Agreement of Protea Vaccine Technologies
July 12, 2009
PDF (English)
PDF (Hebrew)
Read More
Protea Vaccine Technologies sign an exclusive Research and License Option Agreement with GSK for a universal protein-based Pneumococcal vaccine
June 16, 2009
PDF (English)
PDF (Hebrew)
Read More
NasVax commences a Phase I/ IIa dose-optimization clinical study of VaxiSomeTM-adjuvanted Influenza Vaccine. The company presents positive results for VaxiSome in its initial clinical study with intramuscular dosing
October 30, 2008
PDF (English)
PDF (Hebrew)
Read More
Positive preliminary results of a phase 1/2a clinical trial and further clinical trials
August 10, 2008
PDF (English)
PDF (Hebrew)
Read More
NasVax signed a Partnership Agreement with SciGen Ltd. for developing & marketing an Improved Hepatitis B Vaccine
December 09, 2007
PDF (English)
PDF (Hebrew)
Read More
Dr. Ronald Ellis, appointed Senior Vice President & Chief Technical Officer of Israeli Biotechnology Company, NasVax
August 16, 2007
PDF (English)
PDF (Hebrew)
Read More
NasVax receives Ministry of Health Approval for a Phase 1/2a Clinical Study for Improved Flu Vaccine
August 16, 2007
PDF (English)
PDF (Hebrew)
Read More
Erez Chimovits has been appointed CEO NasVax; Dr. Itzik Goldwaser has been appointed President of the Company
March 18, 2007
PDF (English)
PDF (Hebrew)
Read More
NasVax announces Successful Completion of another Pre-Clinical Trial
March 13, 2007
PDF (English)
PDF (Hebrew)
Read More